Teva names Erez Vigodman as President and CEO
9 January 2014 | By Teva
“I would like to welcome Erez to his new position as the CEO of Teva..."
List view / Grid view
News
Allergan’s BOTOX® (botulinum toxin type A) receives national marketing authorisation for treatment of moderate to severe crow’s feet lines in adult patients
9 January 2014 | By Allergan
New aesthetic indication for market-leading neuromodulator which can now help improve appearance of lines around the eyes, as well as treating glabellar frown lines...
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
Daiichi Sankyo, Virtici and Celdara Medical announce collaboration to identify and progress high potential therapeutics
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
Merck receives FDA approval for ISENTRESS® (raltegravir) for pediatric oral suspension
8 January 2014 | By Merck
ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older...
Daclatasvir marketing authorization application for treatment of chronic hepatitis C validated for accelerated regulatory review by the European Medicines Agency
8 January 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4...
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
Quanta Fluid Solutions Ltd – Appointment of new Chief Executive Officer
8 January 2014 | By Quanta Fluid Solutions Ltd
Quanta Fluid Solutions Ltd announces the appointment of John E. Milad as Chief Executive Officer...
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration
7 January 2014 | By Boehringer Ingelheim
Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program...
Sanofi to expand access to Clinical Trial Data
2 January 2014 | By Sanofi
“Sanofi has a history of contributing in this collective effort of sharing clinical trial data and results with researchers and patients with initiatives such as Project Data Sphere..."
GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency
2 January 2014 | By GlaxoSmithKline
GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results...
Romosozumab Phase 2 data published In New England Journal Of Medicine show significant increases in bone mineral density at both spine and hip
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
Lundbeck scientists part of group achieving breakthrough in understanding schizophrenia
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
